To enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public heath concerns, and for other purposes.
15 U.S.C. 12, 26, 45
and
53 21 U.S.C. 355
and
355 42 U.S.C. 262(k)
Document Citations
Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. Senate. Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1224. 116th
Cong., 1st
sess., Introduced in Senate April 29, 2019. https://www.govinfo.gov/app/details/BILLS-116s1224is.
APA
Congress, Senate (2019, April 29). Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S. 1224 (IS)). Retrieved from https://www.govinfo.gov/app/details/BILLS-116s1224is.
MLA
United States, Congress, Senate. Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-116s1224is. 116th Congress, S. 1224, Introduced in Senate 29 Apr. 2019.
Bluebook
S.1224 - 116th Congress (2019-2020): Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act, S.1224, 116th Cong. (2019), https://www.govinfo.gov/app/details/BILLS-116s1224is.
